IBL and Intellect accord for AD MAbs

US firm Intellect Neurosciences has purchased from Japan's Immuno-Biological Laboratories (IBL) the rights to manufacture, develop and commercialize two therapeutic, beta-amyloid specific, humanized monoclonal antibodies for the treatment of Alzheimer's disease. The antibodies are intended as a form of passive immunization to promote the clearance of the endogenous soluble Alzheimer's toxin, beta-amyloid, from the brain, where it causes devastating damage to victims of the disease.

Under the terms of the agreement, Intellect will pay IBL milestone payments related to the development and commercialization of the humanized antibodies and a royalty based on sales of the resulting drug product. In addition, Intellect has granted IBL an exclusive license with respect to certain of its intellectual property related to the antibodies. The license is restricted to the manufacture, use and sale of IBL's murine monoclonal antibodies for research and diagnostic purposes. Intellect is the holder of patents in Japan and other countries related to antibodies and methods of treatment for AD.